Company Profile
CRISPR Therapeutics Stock Price, News & Analysis
- Ticker:
- CRSP
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in Zug, Switzerland and listed on NASDAQ, CRISPR Therapeutics is followed within the gene-editing universe for its platform risk, clinical milestones, and commercial expansion potential.
Stock performance
53.99 USD (-0.68%)
Close
Last updated: June 23, 2026 at 00:00
5.32B USD
Market cap
Why the stock is moving
CRSP is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.
Geographic Base and Sector Classification
Headquartered in Zug, Switzerland and listed on NASDAQ, CRISPR Therapeutics is followed within the gene-editing universe for its platform risk, clinical milestones, and commercial expansion potential.
Business Model Characteristics
CRISPR Therapeutics follows a platform-led model where proof of editing performance, regulatory progress, and partner execution shape the investment case.
Position Within the Biotechnology Landscape
Compared with more mature biotech peers, CRISPR Therapeutics sits near the high-catalyst end of the landscape, where each major update can move the stock sharply.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Source: CRISPR Therapeutics
- 02
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
Source: CRISPR Therapeutics
- 03
- 04
CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Source: CRISPR Therapeutics
- 05
CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones
Source: CRISPR Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics (CRSP) most recently closed at 53.99 USD, a -0.68% move versus the previous session.
What is the market cap of CRISPR Therapeutics (CRSP)?
CRISPR Therapeutics currently has a market capitalization of 5.32B USD on BioPharmSignal.
What does CRISPR Therapeutics do?
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine. Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.
On which exchange is CRSP stock listed?
CRISPR Therapeutics (CRSP) is associated with NASDAQ, Headquartered in Zug, Switzerland and listed on NASDAQ, CRISPR Therapeutics is followed within the gene-editing universe for its platform risk, clinical milestones, and commercial expansion potential., Biotechnology.
What is Therapeutics?
CRISPR Therapeutics is a gene-editing company with exposure to cell therapy and genetic medicine.
Which conditions is CRISPR Therapeutics targeting with Therapeutics?
CRISPR Therapeutics is associated with genetic disease based on its company overview and current catalyst commentary.
What is Investors?
Investors watch the company for how its editing platform broadens beyond the first commercial and clinical milestones.